Professional Documents
Culture Documents
PROCEDURAL MANUAL
Documentation --------------------------------------------------------------------------------------------------- 21
Bipolar Disorder Physicians Manual
Page ii
Appendix B: Communications------------------------------------------------------------------------------ 38
Appendix C: Medication Charts ---------------------------------------------------------------------------- 39
Mood Stabilizers, Anticonvulsants ----------------------------------------------------------------------------------------------------- 40
Antipsychotics, Atypical ----------------------------------------------------------------------------------------------------------------- 42
Antipsychotics, Typical ------------------------------------------------------------------------------------------------------------------ 45
Antidepressants, SSRI-------------------------------------------------------------------------------------------------------------------- 47
Antidepressants, Miscellaneous -------------------------------------------------------------------------------------------------------- 49
Adjunctive Agents ------------------------------------------------------------------------------------------------------------------------ 51
Additional References for Drug Information ----------------------------------------------------------------------------------------- 52
Page iiii
Disclaimer
This manual is based upon the evidence based, expert consensus recommendations
presented in the article, Suppes T, Dennehy E, Hirschfeld RMA, Altshuler LL, Bowden CL,
Calbrese CR, Crismon ML, Ketter T, Sachs G, Swann AC. The Texas Implementation of
Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. J Clin
Psychiatry 2005;60:870-886. The manual also reflects the experiences of the TMAP team in
conducting the research evaluating use of the algorithms, as well as in implementing the
algorithms in public mental health systems. These algorithms reflect the state of knowledge,
current at the time of publication, on effective and appropriate care as well as clinical
consensus judgments when research-based knowledge is lacking. The inevitable changes in
the state of scientific information and technology mandate that periodic review, updating, and
revisions will be needed. These guidelines (algorithms) may not apply to all patients, and each
must be adapted and tailored to each individual patient. The authors bear no responsibility for
the use and/or modification of these guidelines by third parties. The provision of clinical care,
including recommendations contained in these or other guidelines, in whole or in part, is
entirely the responsibility of the clinician.
The Texas Medication Algorithm Project (TMAP) bipolar disorder algorithms and this manual
are copyrighted by the Texas Department of State Health Services (DSHS). If you are using or
adapting the entire manual, sections, tables or figures, please contact us for written
permission. Contact information can be found in Appendix B. Please use proper citation and
acknowledgement of the authors and this manual, when citing or referencing the manual.
Crismon ML, Argo TR, Bendele SD, Suppes T. Texas Medication Algorithm Project Procedural
Manual: Bipolar Disorder Algorithms. The Texas Department of State Health Services. 2007.
Page 1
Author Affiliations
M. Lynn Crismon, PharmD, BCPP
Interim Dean
College of Pharmacy
The University of Texas at Austin
Austin, TX
Tami R. Argo, PharmD, MS, BCPP
Clinical Assistant Professor
College of Pharmacy
The University of Texas at Austin
Austin, TX
Sherrie D Bendele, BS
Project Coordinator
College of Pharmacy
The University of Texas at Austin
Austin, TX
Trisha Suppes, MD, PhD
Professor
Department of Psychiatry
The University of Texas Southwestern Medical Center
Dallas, TX
Financial Disclosures
Dr. Crismon has received grant/research support from Abbott, AstraZeneca, Bristol-Myers
Squibb, Eli Lilly, Forest, Janssen, Pfizer and Shire; and is on the speakers/advisory board of
Astra Zeneca, Corecept Therapeutics, Cyberonics, Elli Lilly, Forest, Janssen, McNeil Specialty
and Consumer Produces, Pfizer and Shire.
Dr. Argo has no significant financial relationships to disclose.
Ms. Bendele has no significant financial relationships to disclose.
Dr. Suppes has received grant/research support from Abbott, AstraZeneca, Bristol-Myers
Squibb, GlaxoSmithKline, Janssen, national Institute of Mental Health, Novartis, Robert Wood
Johnson and the Stanley Medical Research Institute,; has received honoraria from Novartis;
and is a consultant for or on the speakers/advisory board of Abbott, AstraZeneca, BristolMyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Johnson & Johnson, Novartis, Pfizer,
Pharmaceutical Research Institute, Ortho-McNeil, Shire, Solvay and UCB Pharma.
Page 2
State public mental health services are now provided as a component of the Texas Department of State Health
Services (DSHS).
Bipolar Disorder Clinicians Manual
Page 3
in making timely revisions in clinical procedures and budgetary allocations. From a clinical and
administrative perspective, medication algorithms should demonstrate validity with far-reaching
and long-term applications.
For additional information regarding the development of the most current Bipolar I Disorder
Algorithms, please refer to the article: Suppes T, Dennehy E, Hirschfeld RMA, Altshuler LL,
Bowden CL, Calbrese CR, Crismon ML, Ketter T, Sachs G, Swann AC. The Texas
Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I
Disorder. J Clin Psychiatry 2005;60:870-886.
Page 4
Clinical Management
At baseline and throughout treatment, the patient should be evaluated for possible
psychosocial interventions, including evidence based psychotherapy.
Use of the algorithms, assumes that the clinician has made a thorough evaluation and an
accurate diagnosis. If a patient completes trials of two stages of the algorithm without
observable positive outcomes, the patient should be re-evaluated for accuracy of diagnosis
and the occurrence of co-occurring general medical and mental disorders, including
substance abuse.
Brief symptom ratings (BDSS, CGI) should be completed at each visit so that treatment
decisions are guided by objective data.
Adequate documentation should be completed for each algorithm stage and treatment
choice (i.e., decision points). If algorithm stages are skipped or if treatment is different from
the algorithms, the rationale should be adequately documented.
The frequency of clinic visits should be adequate to monitor for symptom changes and
adverse effects, to adjust doses as necessary to achieve an optimum therapeutic trial, and
change regimens when suboptimal clinical response is observed after regimen
optimization.
All patients with bipolar I disorder who achieve a satisfactory clinical response (and
preferably symptom remission) should continue treatment until a full response to treatment
is sustained for at least four weeks. At that point, continuation treatment should begin.
When a choice exists between brand, generic, or different formulations (e.g., slow release)
of a recommended medication, always initiate treatment with the form that is likely to be
best tolerated by the patient, which will lead to enhanced adherence with treatment.
Careful attention should be given to adequate dose and duration of treatment for each
chosen regimen.
Page 5
Assessment Frequency: The Brief Bipolar Disorder Symptom Scale (BDSS) should be
completed at each clinic visit. If the patient is contacted by phone, an Interim Contact Form
(ICF) must be completed.
Criteria for Medication Change: Medication changes are made after evaluation of
tolerability, efficacy across multiple symptom domains, and safety. Clinicians should consult the
Tactics and Critical Decision Points for the Treatment of Bipolar Disorder after review of
symptom patterns and severity on the BDSS score sheet, as well as any medication side
effects and tolerability. The goals of treatment are full symptomatic remission, return of
psychosocial functioning, and prevention of relapses and recurrences. Any symptoms, even
those in the mild to moderate range, warrant consideration of tactics that may further optimize
response. It is appropriate to try more than one combination at a given level. New trials from
each stage can be labeled Stage 2-1, Stage 2-2, etc.
Evaluations: At each visit, a physician will assess core symptom severity, overall functional
impairment, and side effect severity. The Clinical Coordinator (CC) or the physician can
complete the BDSS and patient global self-rating of symptom severity and side effects.
Medication Doses: Appropriate dosage ranges for medications used in the algorithms are
included in Appendix C. Doses outside of the ranges should have a chart note indicating
change from algorithm recommended and documentation of rationale for change. Doses
above the usual therapeutic range should be time limited (e.g., 4-6 weeks), and response to
this dose evaluated using the brief clinical rating scales. If improvement has not occurred with
the higher than usual dosage in this time frame, then treatment should be changed to the next
treatment stage or an alternative medication within the same stage, using an overlap and taper
strategy.
Page 6
Stage 1
Mixed*
Monotherapy
Nonresponse:
Try alternate
monotherapy
1b. OLZ or
CBZ
1b. OLZ or
CBZ
Full
Response
CONT
Partial
Response
Stage 2
Nonresponse:
Try alternate
monotherapy
Full
Response
Partial
Response
Two-Drug Combination
Partial Response
or Nonresponse
Stage 3
Full
Response
CONT
Two-Drug Combination
Full
Response
CONT
Partial Response
or Nonresponse
Stage 4
ECT
or
Add CLOZ
or
Li + (VPA, CBZ or OXC) + AAP
* It is appropriate to try > 1 combination at any given level. New trials from each stage
can be labeled Stage 2 (-1), Stage 2 (-2), etc.
Routine monitoring should occur for patients receiving atypical or typical antipsychotic
treatment
Safety and other concerns led to placement of OLZ and CBZ as alternate first-stage
choices
Bipolar Disorder Clinicians Manual
Page 7
On other antimanic
Increase to 0.8mEq/L
Stage 1
(Continue)
CONT
Full
Response
CONT
Full
Response
CONT
Partial Response
or Nonresponse
Stage 5
Full
Response
Partial Response
or Nonresponse
Stage 4
LTG
QTP* or OFC*
Partial Response
or Nonresponse
Stage 3
On no antimanic,
without history of
severe and/or
recent mania
Antimanic + LTG
Partial Response
or Nonresponse
Stage 2
On no antimanic,
with history of
severe and/or
recent mania
Full
Response
CONT
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Clinical Status
Mild to Moderate
Symptoms
Severe Symptoms
Mild to Moderate
Symptoms
Severe Symptoms
Symptomatic
Week 4
(CDP # 3)
Plan
Mild to Moderate
Symptoms
Severe Symptoms
Severe Symptoms
Page 14
Clinician Ratings
Each of the symptom clusters is rated on a 10-point scale (from no symptoms to extremely
severe). The rating is based on impression of the patient at this visit, as well as information about
the patients clinical status during the week prior to the visit.
Core Symptoms: Based upon all available information, clinician impression of the presence
and severity of each of the symptoms in this patient.
Other Symptoms: Clinician rating of other symptoms associated with the patients disorder,
but not core symptoms of the patients illness. Rate impressions for each of the specific
other symptoms listed (irritability, mood lability, insomnia, agitation, anxiety, level of
interest, appetite, energy level). Under other, specify and rate any other symptom that are
significant.
Overall Side Effect Severity: Overall rating of side effects from all medications being taken
by the patient.
Overall Functioning: Overall impression of this patients ability to function on a daily basis.
10 is the highest possible functioning, and 1 is the lowest possible functioning.
Dennehy EB, Suppes T, Crismon ML, Toprac M, Carmody TJ, Rush AJ. Development of the Brief Bipolar Disorder
Symptom Scale for patients with bipolar disorder. Psychiatry Research 2004;127:137-45.
2
Overall JE, Gorham DR. Introduction - the Brief Psychiatric Rating Scale (BPRS): Recent developments in
ascertainment and scaling. Psychopharmacol Bull 1988;24:97-99.
3
Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating
Scale: The drift busters. Int J Methods Psychiatric Res 1993;221-244.
Bipolar Disorder Clinicians Manual
Page 15
Page 16
Maintenance Treatment
Maintenance treatment recommendations depend on the polarity of the most recent episode, and
levels of recommendations were hierarchically ordered by the TMAP consensus panel. The ordering
reflects the quality and quantity of research evidence balanced with safety and tolerability
information. Maintenance treatment typically begins with the same regimen that the patient received
in acute treatment. Although maintenance treatment research to date has focused on the use of
monotherapy, it is reasonable to start maintenance treatment with the medications that brought the
patient to this point in care. It is likely the majority of patients will need combination treatment to
maintain long-term stability.
The goal of maintenance treatment is to continue treatment at the minimum dose and number of
medications necessary for the patient to attain an optimal quality of life and to prevent relapse.
Thus, unless the patients treatment history dictates otherwise, attempts should be made to simplify
complex medication regimens. Similarly, if higher medication doses were utilized during the acute
Page 17
Page 18
Level I
Evidence:
Lithium or valproate
Alternative
Olanzapinea
Level II
Evidence:
Aripiprazoleb
Level III
Evidence:
Carbamazepine or clozapinea
Level IV
Evidence:
Level V
Evidence:
a
b
Safety issues warrant careful consideration of this option for potential long-term use
Relatively limited information is currently available on this agent in long-term use
Page 19
Level I
Evidence:
Lamotrigine monotherapy
Level II
Evidence:
Lithium
Level III
Evidence:
Level IV
Evidence:
Level V
Evidence
a
b
Safety issues warrant careful consideration of this option for potential long-term use
Relatively limited information is currently available on this agent in long-term use
Page 20
Documentation
Treatment with the bipolar disorder algorithms utilizes uniform documentation developed by
TDSHS and the TMAP team, and modified for use by various centers. The critical information
from patient history needed for implementation of the BDI algorithms is:
1. Past and current psychoactive medications and response
2. Primary current diagnosis. (Please note that these algorithms were developed for
patients diagnosed with bipolar I disorder.)
3. Core symptoms
4. Other symptoms
5. Side effects (to evaluate tolerability)
6. Response to treatment: overall functioning, BDSS scores, patient self-report of
symptom severity and side effects
Outpatient Documentation
Required Forms:
1. Outpatient Clinic Visit Clinical Record Form (CRF): The CRF should be completed at
each visit in which a clinician or other clinician is evaluating response to treatment.
Please note that all patients will have a stage entered for the principal treatment
algorithm.
e.g. Patient is on Stage 3 of the algorithm for Mania/Hypomania/mixed mania.
Stage: 3
CRFs may vary in format, but all should contain the minimum data specified
appendix G. A template CRF is also included.
Optional Forms: If these forms are not used, then an alterative uniform documentation
process should be used to record this important information.
1. Outpatient Intake Form
2. Outpatient Interim Contact Form: In the event that the patient does not come into the
clinic or there is not time for a complete visit, the ICF is documented by or the physician
or other clinical personnel.
Page 21
Documentation
Inpatient Data Collection
Required Forms:
1. Inpatient Clinic Visit Clinical Record Form: Complete as usual. See instructions above
for Outpatient Clinic Visit Clinical Record Form for detailed example.
Optional Forms:
1. Inpatient Intake Form
2. Inpatient Contact Form
Page 22
Page 23
Page 24
Page 25
2.
Not Present
Very Mild
Irritable or grumpy, but not overtly expressed.
Mild
Argumentative or sarcastic.
Moderate
Overtly angry on several occasions OR yelled at others excessively.
Moderately Severe
Has threatened, slammed about or thrown things.
Severe
Has assaulted others but with no harm likely, e.g., slapped or pushed, OR destroyed
property, e.g., knocked over furniture, broken windows.
Extremely Severe
Has attacked others with definite possibility of harming them or with actual harm, e.g.,
assault with hammer or weapon.
Page 26
3.
Not Present
Very Mild
Seems to be very happy, cheerful without much reason.
Mild
Some unaccountable feelings of well-being that persist.
Moderate
Reports excessive or unrealistic feelings of well-being, cheerfulness, confidence or optimism
inappropriate to circumstances, some of the time. May frequently joke, smile, be giddy or
overly enthusiastic OR few instances of marked elevated mood with euphoria.
Moderately Severe
Reports excessive or unrealistic feelings of well-being, confidence or optimism inappropriate
to circumstances much of the time. May describe feeling on top of the world, like
everything is falling into place," or better than ever before, OR several instances of marked
elevated mood with euphoria.
Severe
Reports many instances of marked elevated mood with euphoria OR mood definitely
elevated almost constantly throughout interview and inappropriate to content.
Extremely Severe
Patient reports being elated or appears almost intoxicated, laughing, joking, giggling,
constantly euphoric, feeling invulnerable, all inappropriate to immediate circumstances.
Not Present
Very Mild
Feels great and denies obvious problems, but not unrealistic.
Mild
Exaggerated self-opinion beyond abilities and training.
Page 27
4.
Moderate
Inappropriate boastfulness, claims to be brilliant, insightful, or gifted beyond realistic
proportions, but rarely self-discloses or acts on these inflated self-concepts. Does not claim
that grandiose accomplishments have actually occurred.
Moderately Severe
Same as 4 but often self-discloses and acts on these grandiose ideas. May have doubts
about the reality of the grandiose ideas. Not delusional.
Severe
Delusional--claims to have special powers like ESP, to have millions of dollars, invented new
machines, worked at jobs when it is known that he was never employed in these capacities,
be Jesus Christ, or the President. Patient may not be very preoccupied.
Extremely Severe
Delusional--Same as 6 but subject seems very preoccupied and tends to disclose or act on
grandiose delusions.
Not Present
Very Mild
Occasionally feels sad, unhappy or depressed.
Mild
Frequently feels sad or unhappy but can readily turn attention to other things.
Moderate
Frequent periods of feeling very sad, unhappy, moderately depressed, but able to function
with extra effort.
Moderately Severe
Frequent, but not daily, periods of deep depression OR some areas of functioning are
disrupted by depression.
Page 28
5.
Severe
Deeply depressed daily but not persisting throughout the day OR many areas of functioning
are disrupted by depression.
Extremely Severe
Deeply depressed daily OR most areas of functioning are disrupted by depression.
ANXIETY: Reported apprehension, tension, fear, panic or worry. Rate only the patient's
statements, not observed anxiety that is rated under TENSION.
Have you been worried a lot during [mention time frame]? Have you been nervous or
apprehensive? (What do you worry about?)
Are you concerned about anything? How about finances or the future?
When you are feeling nervous, do your palms sweat or does your heart beat fast (or shortness
of breath, trembling, choking)?
[If patient reports anxiety or autonomic accompaniment, ask the following];
How much of the time have you been [use patient's description]?
Has it interfered with your ability to perform your usual activitieslwork?
NA Not assessed
6.
Not Present
Very Mild
Reports some discomfort due to worry OR infrequent worries that occur more than usual for
most normal individuals.
Mild
Worried frequently but can readily turn attention to other things.
Moderate
Worried most of the time and cannot turn attention to other things easily but no impairment
in functioning OR occasional anxiety with autonomic accompaniment but no impairment in
functioning.
Moderately Severe
Frequent, but not daily, periods of anxiety with autonomic accompaniment, OR some areas
of functioning are disrupted by anxiety or worry.
Severe
Anxiety with autonomic accompaniment daily but not persisting throughout the day OR
many areas of functioning are disrupted by anxiety or constant worry.
Extremely Severe
Anxiety with autonomic accompaniment persisting throughout the day OR most areas of
functioning are disrupted by anxiety or constant worry.
UNUSUAL THOUGHT CONTENT: Unusual, odd, strange or bizarre thought content. Rate the
degree of unusualness, not the degree of disorganization of speech. Delusions are patently
Page 29
absurd, clearly false or bizarre ideas that are expressed with full conviction. Consider the patient
to have full conviction if he/she has acted as though the delusional belief were true. Ideas of
reference/persecution can be differentiated from delusions in that ideas are expressed with
much doubt and contain more elements of reality. Include thought insertion, withdrawal and
broadcast. Include grandiose, somatic and persecutory delusions even if rated elsewhere.
Note: If Somatic Concern, Guilt, Suspiciousness, or Grandiosity are rated 6 or 7" due to
delusions, then Unusual Thought Content must be rated a 4" or above.
Have you been receiving any special messages from people or from the way things are
arranged around you? Have you seen any references to yourself on TV or in the
newspapers?
Can anyone read your mind?
Do you have a special relationship with God?
Is anything like electricity, X-rays, or radio waves affecting you?
Are thoughts put into your head that are not your own?
Have you felt that you were under the control of another person or force?
[If patient reports any odd ideas/delusions, ask the following]:
How often do you think about [use patient's description]?
Have you told anyone about these experiences? How do you explain the things that have been
happening [specify]?
NA Not assessed
1
Not Present
Very Mild
Ideas of reference (people may stare or may laugh at him), ideas of persecution (people
may mistreat him). Unusual beliefs in psychic powers, spirits, UFOs, or unrealistic beliefs in
one's own abilities. Not strongly held. Some doubt.
Mild
Same as 2, but degree of reality distortion is more severe as indicated by highly unusual
ideas or greater conviction. Content may be typical of delusions (even bizarre), but without
full conviction. The delusion does not seem to have fully formed, but is considered as one
possible explanation for an unusual experience.
Moderate
Delusion present but no preoccupation or functional impairment. May be an encapsulated
delusion or a firmly endorsed absurd belief about past delusional circumstances.
Moderately Severe
Full delusion(s) present with some preoccupation OR some areas of functioning disrupted
by delusional thinking.
Severe
Full delusion(s) present with much preoccupation OR many areas of functioning are
disrupted by delusional thinking.
Page 30
Extremely Severe
Full delusions present with almost total preoccupation OR most areas of functioning are
disrupted by delusional thinking.
Rate the following items on the basis of observed behavior and speech.
7. EXCITEMENT: Heightened emotional tone, or increased emotional reactivity to interviewer or
topics being discussed, as evidenced by increased intensity of facial expressions, voice tone,
expressive gestures or increase in speech quantity and speed.
NA Not assessed
8.
Not Present
Very Mild
Subtle and fleeting or questionable increase in emotional intensity. For example, at times,
seems keyed-up or overly alert.
Mild
Subtle but persistent increase in emotional intensity. For example, lively use of gestures and
variation in voice tone.
Moderate
Definite but occasional increase in emotional intensity. For example, reacts to interviewer or
topics that are discussed with noticeable emotional intensity. Some pressured speech.
Moderately Severe
Definite and persistent increase in emotional intensity. For example, reacts to many stimuli,
whether relevant or not, with considerable emotional intensity. Frequent pressured speech.
Severe
Marked increase in emotional intensity. For example reacts to most stimuli with
inappropriate emotional intensity. Has difficulty settling down or staying on task. Often
restless, impulsive, or speech is often pressured.
Extremely Severe
Marked and persistent increase in emotional intensity. Reacts to all stimuli with inappropriate
intensity, impulsiveness. Cannot settle down or stay on task. Very restless and impulsive
most of the time. Constant pressured speech.
Not Present
Very Mild
Some restlessness, difficulty sitting still, lively facial expressions, or somewhat talkative.
Page 31
9.
Mild
Occasionally very restless, definite increase in motor activity, lively gestures, 1-3 brief
instances of pressured speech.
Moderate
Very restless, fidgety, excessive facial expressions or nonproductive and repetitious motor
movements. Much pressured speech, up to one third of the interview.
Moderately Severe
Frequently restless, fidgety. Many instances of excessive non-productive and repetitious
motor movements. On the move most of the time. Frequent pressured speech, difficult to
interrupt. Rises on 1-2 occasions to pace.
Severe
Excessive motor activity, restlessness, fidgety, loud tapping, noisy, etc., throughout most of
the interview. Speech can only be interrupted with much effort. Rises on 3-4 occasions to
pace.
Extremely Severe
Constant excessive motor activity throughout entire interview, e.g., constant pacing,
constant pressured speech with no pauses, interviewee can only be interrupted briefly and
only small amounts of relevant information can be obtained.
Not Present
Very Mild
Lack of emotional involvement shown by occasional failure to make reciprocal comments,
occasionally appearing preoccupied, or smiling in a stilted manner, but spontaneously
engages the interviewer most of the time.
Mild
Lack of emotional involvement shown by noticeable failure to make reciprocal comments,
appearing preoccupied, or lacking in warmth, but responds to interviewer when approached.
Moderate
Emotional contact not present much of the interview because subject does not elaborate
responses, fails to make eye contact, doesn't seem to care if interviewer is listening, or may
be preoccupied with psychotic material.
Moderately Severe
Same as 4 but emotional contact not present most of the interview.
Severe
Actively avoids emotional participation. Frequently unresponsive or responds with yes/no
answers (not solely due to persecutory delusions). Responds with only minimal affect.
Page 32
10.
Extremely Severe
Consistently avoids emotional participation. Unresponsive or responds with yes/no answers
(not solely due to persecutory delusions). May leave during interview or just not respond at
all.
BLUNTED AFFECT: Restricted range in emotional expressiveness of face, voice, and gestures.
Marked indifference or flatness even when discussing distressing topics. In the case of euphoric
or dysphoric patients, rate Blunted Affect if a flat quality is also clearly present.
Use the following probes at end of interview to assess emotional responsivity:
Have you heard any good jokes lately? Would you like to hear a joke?
NA Not assessed
1
Not Present
Very Mild
Emotional range is slightly subdued or reserved but displays appropriate facial expressions
and tone of voice that are within normal limits.
Mild
Emotional range overall is diminished, subdued, or reserved, without many spontaneous
and appropriate emotional responses. Voice tone is slightly monotonous.
Moderate
Emotional range is noticeably diminished, patient doesn't show emotion, smile, or react to
distressing topics except infrequently. Voice tone is monotonous or there is noticeable
decrease in spontaneous movements. Displays of emotion or gestures are usually followed
by a return to flattened affect.
Moderately Severe
Emotional range very diminished, patient doesn't show emotion, smile or react to distressing
topics except minimally, few gestures, facial expression does not change very often. Voice
tone is monotonous much of the time.
Severe
Very little emotional range or expression. Mechanical in speech and gestures most of the
time. Unchanging facial expression. Voice tone is monotonous most of the time.
Extremely Severe
Virtually no emotional range or expressiveness, stiff movements. Voice tone is monotonous
all of the time.
Page 33
Page 34
Presence of Mild to
Moderate Symptoms
may indicate need for
medication adjustment.
Symptom Group
Symptoms
NA
Very Mild
Mild
Moderate
Moderately
Severe
Severe
Extremely
Severe
Hostility
Elevated Mood
Manic/Hypomanic Grandiosity
Excitement
Motor Hyperactivity
Depressed Mood
Major Depressive
Anxiety
Emotional Withdrawal
Blunted Affect
Psychotic
Page 35
Week 0: CDP #1
Symptomatic
Week 2: CDP #2
Order serum
concentrations (if
applicable) to adjust dose.
NA
Mild
Moderate Moderately
Severe
Severe
Extremely
Severe
Start medications
Start medications
Week 4: CDP #3
Order serum
concentrations (if
applicable) to adjust dose.
Week 6: CDP #4
Go to next stage.
Week 8: CDP #5
* Side Effects: Treatment recommendations assume that side effects are tolerable. Refer to the Side Effects Management section of the physician
manual.Intolerable, unmanageable side effects may warrant changing to a different stage of treatment. Tolerability should be evaluated at all Critical Decision
Points.
Once a patient sustains a full response to medication for at least four weeks, a transition to continuation treatment occurs. In general, the patient should have full
response for two consecutive visits before beginning continuation treatment. After maintaining a full response for 4-6 months, the clinician should consider
medication dosage reduction or regimen simplification in maintenance phase treatment.
Page 36
Scoring Criteria
for Physician and Patient
Overall Symptom and
Side Effect Ratings
0
No Symptoms
Borderline
Mild
Mild Moderate
Moderate
Moderate Marked
Marked
Marked Severe
Severe
Severe Extreme
10 =
Extreme
Page 37
Appendix B: Communications
TMAP Information
The University of Texas at Austin
College of Pharmacy PHR 5.110
1 University Station A1910
Austin, TX 78712
TMAP Phone: 512-232-5986
TMAP Email: info@WebTMAP.org
Page 38
Page 39
Carbamazepine
Generic available
Tegretol
Tegretol XR
Carbatrol
Equetro
Starting
Dose
200-600
mg/day
Titration
200
mg/day
every
2-4 days
Target Dose
or Range
400-1600
mg/day
Maximum
Daily Dose
1600
1
mg/day
Schedule
2 - 3 times
daily
Divalproex
Sodium
(Valproate)
Depakote
500 - 1000
mg/day
500
mg/day
every
12
weeks
750-2000
mg/day
60
1
mg/kg/day
Twice daily
or nightly
Side Effects
Ataxia
Diplopia
Dizziness
Dysarthria
GI upset
Hyponatremia
Leukopenia
Nystagmus
Rash
Sedation
Alopecia
Ataxia
Cognitive impairment
Dizziness
GI upset
Hepatitis
Pancreatitis
Polycystic ovarian
syndrome
Rash
Somnolence
Thrombocytopenia
Tremor
Weight gain
Antipsychotics
Benzodiazepines
Cimetidine
Corticosteroids
Valproate
Erythromycin
Lamotrigine3
Oral contraceptive pill
SSRIs
Tricyclic
antidepressants
Warfarin
Induces its own
metabolism. May
require close dose
titration.
Antipsychotics
Benzodiazepines
Carbamazepine
Lamotrigine4
Lithium
MAOIs
Phenytoin
Tricyclic
antidepressants
Warfarin
Maximum daily dosage should be based upon the medication serum concentration in the individual patient in the context of clinical response and tolerability.
Therapeutic serum concentration monitoring of mood stabilizers should be drawn 12-hours after the last dose.
3
Recommended dose titration of lamotrigine for patients taking carbamazepine (or other enzyme-inducing drugs) and not taking valproate: 50mg daily for weeks 1 & 2; 100 mg daily (in divided doses)
for weeks 3 & 4; 200 mg daily (in divided doses) for week 5; 300 mg daily (in divided doses) for week 6; up to 400 mg daily (in divided doses) for week 7 and thereafter.
4
Recommended dose titration of lamotrigine for patients taking valproate or other forms of valproic acid: 25 mg every other day for weeks 1 & 2; 25 mg daily for weeks 3 & 4; 50 mg daily for week 5;
100mg daily for week 6 and thereafter.
2
Page 40
Lamotrigine
Generic available
Lamictal
Lithium
Generic available
Eskalith
Eskalith CR
Lithobid
Starting
Dose
25 mg/day
900
mg/day
Titration
25 mg/day
every
14 days
check
serum
concentrati
on at 3-4
days and
adjust
(linear
kinetics)
Target Dose
or Range
200
mg/day
900-2400
mg/day
Maximum
Daily Dose
400
mg/day
3600
5
mg/day
Schedule
Once or
twice daily
Once or
twice daily
Oxcarbazepine
Trileptal
600
mg/day
600
mg/day
every
7 days
600-2100
mg/day
2400
mg/day
2 - 3 times
daily
Side Effects
Ataxia
Dizziness
Headache
Nausea
Rash
Somnolence
Stevens Johnson
Syndrome
Carbamazepine2
Valproate3
Acne
Acute renal dysfunction
Cognition
Diarrhea
Dizziness
ECG changes
GI upset
Hypothyroidism
Nausea
Polyuria
Sedation
Thirst
Tremor
Weight gain
Ataxia
Diplopia
Dizziness
GI upset
Hyponatremia
Somnolence
Tremor
Antipsychotics
Dihydropyridine calcium
antagonists
Oral contraceptive pill
Vitamin D
ACE-inhibitors
Caffeine
NSAIDs
Osmotic diuretics
Theophylline
Thiazide diuretics
Maximum daily dosage should be based upon the medication serum concentration in the individual patient in the context of clinical response and tolerability.
Page 41
Starting
Dose
Titration
Target Dose
or Range
Maximum
Daily Dose
Schedule
Aripiprazole
Abilify
15 mg/day
5-15
mg/day
15-30
mg/day
30 mg/day
Once daily
Olanzapine
Zyprexa
5-10
mg/day
5 mg/day
5-20
mg/day
20 mg/day
Once daily
Quetiapine
Seroquel
100
mg/day
550-800
mg/day:
mania
300-800
mg/day
100
mg/day
x 3 days,
then 200
mg/day
800
mg/day
Twice daily
300-800
mg/day:
depression
Risperidone
Risperdal
1-2 mg/day
1-2 mg/day
4-6 mg/day
8 mg/day
Once or
twice daily
Side Effects
Agitation
Constipation
EPS
Insomnia
Nausea
Somnolence
Constipation
Dizziness
Dry Mouth
Glucose dysregulation
Hyperlipidemia
Increased appetite
Sedation
Weight Gain
Cataract Formation
Dry mouth
Glucose dysregulation
Headache
Hyperlipidemia
Increased appetite
Orthostatic hypotension
Sedation
Weight gain
Erythromycin
Fluconazole
Ketoconazole
Phenytoin
St. Johns Wort
Thioridazine
Valproate
EPS
Glucose dysregulation
Galactorrhea
Hyperlipidemia
Menstrual irregularity
Orthostatic hypotension
Prolactin elevation
Sedation
Sexual dysfunction
Tardive dyskinesia
Weight gain
Carbamazepine
Cimetidine
Fluoxetine
Paroxetine
Phenytoin
Rifampin
Tricyclic
antidepressants
Carbamazepine
Fluoxetine
Ketoconazole
Paroxetine
Quinidine
St Johns Wort
Carbamazepine
Fluvoxamine
Rifampin
Smoking
St. Johns Wort
Page 42
Risperidone
Risperdal
Consta
Ziprasidone
Geodon
Starting
Dose
25 mg (IM)
80 mg/day
Titration
N/A
20-40
mg/day
Target Dose
or Range
25 50 mg
(IM)
120
mg/day
Maximum
Daily Dose
50 mg (IM)
200
mg/day
Schedule
Every
2 weeks
Twice
7
daily
Side Effects
EPS
Glucose dysregulation
Galactorrhea
Hyperlipidemia
Menstrual irregularity
Orthostatic hypotension
Prolactin elevation
Sedation
Sexual dysfunction
Tardive dyskinesia
Weight gain
Dizziness
ECG changes
EPS
Rash
Sedation
Vomiting
Carbamazepine
Cimetidine
Fluoxetine
Paroxetine
Phenytoin
Rifampin
Tricyclic
antidepressants
Carbamazepine
Diuretics
Moxifloxacin
Quinidine
Sotalol
Thioridazine
Tricyclic
antidepressants
Page 43
Starting
Dose
Titration
Target Dose
or Range
Maximum
Daily Dose
Schedule
Side Effects
Clozapine
Generic available
Clozaril
Fazaclo
12.5-25
mg/day
25 mg/day
every
2-3 days
100-400
mg/day
900
mg/day
1 - 3 times
daily
Agranulocytosis
Excess salivation
Fever
Glucose dysregulation
Hyperlipidemia
Increased appetite
Myocarditis
Orthostatic hypotension
Sedation
Seizures
Tachycardia
Weight gain
Barbiturates
Caffeine
Carbamazepine
Cimetidine
Erythromycin
Phenytoin
Rifampin
Ritonavir
Smoking
SSRIs
St. Johns Wort
Page 44
Starting
Dose
Target
Dose or
Range
Titration
Maximum
Daily Dose
Schedule
Side Effects
Low Potency
Chlorpromazine
Generic available
Thorazine
300
mg/day
100-200
mg/day
400-1000
mg/day
2000
mg/day
Three
times daily
6-8 mg/day
4-8 mg/day
24
mg/day
64 mg/day
Three
times daily
2.5 mg
2.5-5
mg/day
2.5-20
mg/day
Constipation
Dry mouth
EPS
Orthostatic
hypotension
Photosensitivity
Sedation
Tachycardia
Tardive dyskinesia
Paroxetine
Quinolones
High Potency
Fluphenazine
Generic available
Prolixin
Guanethidine
Meperidine
Paroxetine
Pindolol
Quinolones
Beta-Blockers
Ziprasidone
Mid Potency
Perphenazine
Generic available
Trilafon
40 mg/day
Three
times daily
Page 45
Guanethidine
Paroxetine
Quinolones
Starting
Dose
Titration
Target
Dose or
Range
Fluphenazine D
Generic available
Prolixin
Decanoate
12.5-25
mg IM
every 1-3
8
weeks
12.5 mg
per
injection
6.25-50
mg IM
every 2-4
weeks
Maximum
Daily Dose
Schedule
100mg IM
(per 4
weeks)
Every
1-3 weeks
Side Effects
Guanethidine
Paroxetine
Quinolones
9) Vision questionnaire ask whether the patient has
experienced a change in vision and should specifically
ask about distance vision and blurry vision yearly
10) Ocular evaluations yearly for patients older than
age 40 years; every 2 years for younger patients
Haloperidol
Generic available
Haldol
2 mg/day
Haloperidol D
Generic available
Haldol
Decanoate
25-50 mg
IM every 24
9,10,11
weeks
2-5 mg/day
2-20
mg/day
40 mg/day
N/A
50-200 mg
IM every 24 weeks
450 mg
(per 4
weeks)
1 - 3 times
daily
Every
3-4 weeks
Azole antifungals
Carbamazepine
Rifabutin
Rifampin
Azole antifungals
Carbamazepine
Rifabutin
Rifampin
Page 46
Citalopram
Generic available
Celexa
Escitalopram
Lexapro
Fluoxetine
Generic available
Prozac
Starting
Dose
20 mg/day
10 mg/day
20 mg/day
Titration
10 mg
every
2 weeks
10 mg
every
2 weeks
10-20 mg
every
4 weeks
Target
Dose or
Range
20-40
mg/day
10-20
mg/day
20-40
mg/day
Maximum
Daily Dose
60 mg/day
20 mg/day
80 mg/day
Schedule
Side Effects
Once daily
Once daily
Once daily
Page 47
Agitation
Constipation
Diarrhea
Dizziness
Dry Mouth
Fatigue
Headache
Insomnia
Loss of appetite
Nausea
Nervousness
Sexual dysfunction
Somnolence
Sweating
Clozapine
Cyclosporine
Linezolid
MAOIs
NSAIDs
Pimozide
St. Johns Wort
Sympathomimetics
Tramadol
Triptans
Cyclosporine
Linezolid
MAOIs
NSAIDs
St. Johns Wort
Sympathomimetics
Tramadol
Triptans
Carbamazepine
Clozapine
Cyclosporine
Hydantoins
Linezolid
MAOIs
NSAIDs
St. Johns Wort
Sympathomimetics
Thioridazine
Tramadol
Triptans
Tricyclic
antidepressants
Fluvoxamine
Generic available
Luvox
Paroxetine
Generic
12
available
Paxil
Paxil CR
Sertraline
Generic available
Zoloft
12
Starting
Dose
50 mg/day
20 mg/day
50 mg/day
Titration
50-100 mg
every
2 weeks
10-20 mg
every
2 weeks
50-100 mg
every
2 weeks
Target
Dose or
Range
Maximum
Daily Dose
100-200
mg/day
300
mg/day
Schedule
Once or
twice daily
50 mg/day
50-150
mg/day
200
mg/day
Side Effects
Once daily
Once daily
Carbamazepine
Clozapine
Cyclosporine
Grapefruit
Hydantoins
Linezolid
MAOIs
Methadone
NSAIDs
Ropivacaine
St. Johns Wort
Sympathomimetics
Tacrine
Theophyllines
Thioridazine
Tizanidine
Tramadol
Triptans
Tricyclic
antidepressants
Cyclosporine
Linezolid
MAOIs
NSAIDs
Phenothiazines
St. Johns Wort
Sympathomimetics
Tramadol
Triptans
Tricyclic
antidepressants
Carbamazepine
Clozapine
Cyclosporine
Grapefruit
Hydantoins
Linezolid
MAOIs
NSAIDs
Phenothiazines
Pimozide
St. Johns Wort
Sympathomimetics
Tramadol
Triptans
Tricyclic
antidepressants
Page 48
Bupropion
Generic available
Wellbutrin SR
Wellbutrin XL
Venlafaxine
13
Generic available
Effexor
Effexor XR
Phenelzine
Nardil
Starting
Dose
Titration
150
mg/day
150
mg/day
at
3-7 days
37.5
mg/day
37.5
75 mg/day
every
5-7 days
45 mg/day
15
mg/week
Target
Dose or
Range
300
mg/day
Maximum
Daily Dose
Schedule
400
mg/day
Twice daily
(SR)
450
mg/day(XL
)
Once daily
(XL)
150-225
mg/day
60-90
mg/day
375
mg/day
90 mg/day
Once daily
13
20-30
mg/day
10
mg/week
20-40
mg/day
60 mg/day
Constipation
Dry mouth
Headache
Insomnia
Nausea
Seizures
Anxiety
Decreased appetite
Dizziness
Insomnia
Nausea
Sweating
2 - 3 times
daily
1) Blood chemistries with emphasis on hepatic and renal
functions; baseline, yearly and as clinically indicated
during prolonged or high dose therapy
Tranylcypromine
Generic available
Parnate
Side Effects
2 - 3 times
daily
Edema
Insomnia
Orthostatic
hypotension
Sexual dysfunction
Weight gain
Carbamazepine
Cyclosporine
Linezolid
MAOIs
Ritonavir
Tricyclic
antidepressants
Linezolid
MAOIs
St. Johns Wort
Sympathomimetics
Tramadol
Triptans
Atomoxetine
Bupropion
Carbamazepine
Dextromethorphan
Insulins
Levodopa
Linezolid
Meperidine
SSRIs
St. Johns Wort
Sulfonylureas
Sympathomimetics
Tramadol
Triptans
Tricyclic
antidepressants
Tyramine foods
Venlafaxine
Page 49
Starting
Dose
Titration
25-75
mg/day
25-50
mg/day
every
1-2 days
Target
Dose or
Range
Maximum
Daily Dose
Schedule
Side Effects
Amitriptyline
Generic available
Elavil
150
mg/day
300
mg/day
Once daily
Desipramine
Generic available
Norpramin
Pertofrane
25-75
mg/day
25-50
mg/day
every
1-2 days
150
mg/day
300
mg/day
Once daily
Doxepin
Generic available
Sinequan
25-75
mg/day
25-50
mg/day
every
1-2 days
150
mg/day
300
mg/day
Once or
twice daily
Blurred Vision
Constipation
Dry Mouth
Orthostatic hypotension
Sedation
Tachycardia
Urinary retention
Weight gain
Carbamazepine
Ciimetidine
Clonidine
Fluoxetine
Guanethidine
Linezolid
MAOIs
Paroxetine
Procainamide
Quinidine
Quinolones
Rifabutin
Rifampin
St. Johns Wort
Sympathomimetics
Valproate
Ziprasidone
Nortriptyline
Generic available
Pamelor
Aventyl
25 mg/day
25 mg/day
every
2 days
75 mg/day
200
mg/day
Once daily
** Therapeutic drug monitoring of tricyclic antidepressants can be performed after 5-7 days of consistent dosing. Dosing adjustments should be made to achieve 12-hour blood levels within a therapeutic
range.
Page 50
Titration
Pramipexole
Mirapex
0.375
mg/day
0.375
mg/day
every 7
days
1-3 mg/day
5 mg/day
1 - 3 times
daily
None
Inositol
6 g/day
6 g/day
at 7 days
12-14
g/day
None
Three
times daily
None
Diarrhea
Nausea
Unknown
Anorexia
Insomnia
Nervousness
Psychosis
Tachycardia
Guanethidine
MAOIs
SSRIs
Urinary Alkalinizers
2 - 3 times
daily
Anorexia
Insomnia
Nervousness
Psychosis
Tachycardia
Guanethidine
Hydantoins
MAOIs
Tricyclic
antidepressants
Once daily
None
Diarrhea
Headache
Irritability
Nervousness
Sweating
Tachycardia
Anticoagulants
Hypoglycemics
Oral contraceptives
Tricyclic
antidepressants
None
Diarrhea
Headache
Irritability
Nervousness
Sweating
Tachycardia
Anticoagulants
Cholestyramine
Digoxin
Estrogens
Iron
Theophyllines
Drug
Amphetamine
Mixed Salts
Generic available
Adderall XR
Methylphenidate
Generic
14
available
Ritalin
Ritalin SR
Concerta
T3
(Liothyronine)
Generic available
Cytomel
Triostat
T4
(Levothyroxine)
Generic available
Synthroid
Levoxyl
14
10 mg/day
None
Target Dose
or Range
10-60
mg/day
Maximum
Daily Dose
60 mg/day
Schedule
2 - 3 times
daily
Side Effects
Constipation
Insomnia
Nausea
Psychosis
Somnolence
Cimetidine
Diltiazem
Ranitidine
Triamterene
Verapamil
20 mg/day
None
25
mcg/day
None
50
mcg/day
50
mcg/day
every 3
days
20-40
mg/day
25-50
mcg/day
300-500
mcg/day
60 mg/day
160
mg/day
500
mcg/day
Once daily
Page 51
Page 52
Side Effect
Recommendations
- Nausea and diarrhea are usually transient side effects with antidepressants,
and improvement should occur within 2-3 weeks after initiation or dose
increases.
GI Upset
Tremor
Sedation
Page 53
Side Effect
Recommendations
- Usually seen with typical antipsychotics or higher doses of risperidone.
- Parkinsonian tremor coarse tremor at rest of approximately 4-6 Hz.
Decrease dose, divide dosing, use bedtime dosing, or switch to alternate
medication.
Extrapyramidal
Symptoms
(EPS)
Parkinsonian
Tremor, Akathisia,
and Dystonia
- Patients with a history of NMS should be educated about the need to stay well
hydrated and avoid strenuous physical activity when outside during hot
weather.
- If the patient has been on a FGA, changing to a SGA is reasonable.
- May consider switching to an alternative medication with lower propensity to
cause sexual dysfunction.
- If SSRI-induced sexual dysfunction, may consider adding bupropion 75-150mg
daily.
Sexual
Dysfunction
Page 54
Side Effect
Recommendations
- Promote good sleep hygiene:
Encourage regular aerobic exercise at least four hours before bedtime.
Avoid alcoholic beverages.
Encourage regular sleep cycles.
Eliminate noises and distracting lights.
Engage in relaxing activities before bed (reading, sex, meditation, etc).
Try a glass of warm milk.
- If due to concomitant antidepressant use: reduce the dose of antidepressant, if
possible.
Insomnia
Weight Gain
Decrease excess fats (decrease fried foods, eat lean meats, increase
vegetables, salads, and fruits).
Decrease excessive low nutritional content carbohydrate (soft drinks,
deserts, candy, gravies, potatoes, white bread).
- Avoid snacking, and particularly, no evening snacks.
Page 55
Co-Existing
Symptom
Agitation/
Excitement
Persistent
symptoms of
Aggression/Hostility/
Mood Lability
Depression
Recommendations
- Consider adjunctive medications, including as needed use of oral and intramuscular
medications including benzodiazepines, typical antipsychotics, and atypical
antipsychotics:
Lorazepam 1-4 mg or clonazepam 0.5-2 mg may be used in treating acute
agitation. In emergent situations where rapid reduction of agitation is necessary,
lorazapam 1-2 mg given intramuscularly may be preferable to oral dosing. The
dose may be repeated every 1-2 hours as needed, and onset of effect is
generally seen within 15-30 minutes.
Haloperidol 5 mg orally or intramuscularly may be given every 30-60 minutes
until patient is calm.
Atypical antipsychotics in intramuscular or oral formulations may be given on an
as needed basis to control acute agitation. If oral dosing is used, doses should
be initiated at the low end of the dosing range. Intramuscular olanzapine,
risperidone oral solution, and intramuscular ziprasidone act more rapidly than
their oral counterparts and their use may be warranted in cases where the
patient can not tolerate or does not respond to typical antipsychotic agents
and/or benzodiazepines.
o Intramuscular olanzapine 2.5-10 mg, may repeat 2 hours after initial
dose and 4 hours after second dose, with a maximum of 30 mg daily.
o Intramuscular ziprasidone 10-20 mg as needed to a maximum dose of
40 mg daily. The 10 mg dose may be given every 2 hours, and the 20
mg dose may be given every 4 hours.
o Intramuscular aripiprazole 5.25 9.75 mg as needed every two hours
to a maximum of 30 mg daily.
Risperidone oral solution is available in 1mg/mL.
- Failure of the first trial of pharmacotherapy should be followed by a second trial of an
alternative agent above.
- After failure of multiple trials of agents to control acute agitiation/excitement,
consider moving treatment to the next algorithm stage.
Lithium, valproate and carbamazepine are all therapeutic options for the
management of aggression and hostility associated with acute exacerbations in
schizophrenia
If there is no discernible change in the clinical picture after 1-3 weeks, the clinician
should discontinue the adjuvant mood stabilizer and consider switching the patient to
clozapine.
Medication treatments for depression in schizophrenia are the same as those used
in major depressive disorder.
SSRIs, venlafaxine XR, bupropion SR/XL, duloxetine and mirtazapine are
recommended as first line treatments.
Page 56
Co-Existing
Symptom
Recommendations
- Promote good sleep hygiene:
Encourage regular aerobic exercise at least four hours before bedtime.
Avoid alcoholic beverages.
Encourage regular sleep cycles.
Eliminate noises and distracting lights.
Engage in relaxing activities before bed (reading, sex, meditation, etc.).
Try a glass of milk.
- Adjunctive medications:
Insomnia
Page 57
Page 58
Page 59
Rush AJ, Crismon ML, Toprac MG, Shon SP, Rago WV, Miller AL, Suppes T, Trivedi MH, Biggs MM,
Shores-Wilson K, Kashner TM, Altshuler KZ. Implementing guidelines and systems of care:
Experiences with the Texas Medication Algorithm Project (TMAP). Journal of Practical Psychiatry
& Behavioral Health 1999;5:75-86.
Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann A,
Biggs MM, Shores-Wilson K, Kashner M, Pigott TA, Chiles CA, Gilbert DA, Altshuler KZ.
Medication treatment for the severely and persistently mentally ill: The Texas Medication
Algorithm Project. Journal of Clinical Psychiatry 1999;60:284-291.
Shon SP, Crismon ML, Toprac MG, Trivedi M, Miller AL, Suppes T, Rush AJ. Mental health care from
the public perspective: The Texas Medication Algorithm Project. Journal of Clinical Psychiatry
1999;60 (suppl 3):16-20.
Shon SP, Toprac MG, Crismon ML, Rush AJ. Strategies for implementing psychiatric medication
algorithms in the public sector. Journal of Practical Psychiatry & Behavioral Health 1999;5:32-36.
Starkweather K, Shon SP, Crismon ML. A Texas-sized prescription: providers report progress with
medication guidelines. Behavioral Healthcare Tomorrow 2000;9(4):44-46.
Starkweather K, Shon SP. Implementing Medication Algorithms: The Texas Experience. Psychiatrist
Administrator 2001;1:13-18.
Suppes T, Dennehy E, Hirschfeld RMA, Altshuler LL, Bowden CL, Calbrese CR, Crismon ML, Ketter
T, Sachs G, Swann AC. The Texas implementation of medication algorithms: Update to the
algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;60:870-886.
Suppes T, Dennehy E, Rush AJ, Crismon ML, Kashner, TM, Carmody TJ, Toprac MG, Biggs MM,
Shores-Wilson K, Witte B, Trivedi MH, Steven SP. Texas Medication Algorithm Project: clinical
results for patients with a history of mania. Journal of Clinical Psychiatry 2003;64:370-82.
Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, Toprac MG, Rush AJ,
Shon SP, Altshuler KZ. Texas Medication Algorithm Project development and feasibility testing
of a treatment algorithm for patients with bipolar disorder. Journal of Clinical Psychiatry
2001;62:439-447.
Toprac MG, Rush AJ, Conner TM, Crismon ML, Dees M, Hopkins C, Rowe V, Shon SP. The Texas
Medication Algorithm Project patient and family education program: a consumer-guided initiative.
Journal of Clinical Psychiatry 2000;61:477-486.
Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes T, Rush AJ.
Implementation of the Texas Medication Algorithm Project Patient and Family Education
Program. J Clin Psychiatry 2006;67:1362-1372.
Trivedi MH, Rush AJ, Crismon ML, ONeal B, Toprac MG. Treatment guidelines and algorithms. In:
Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual Review of
Drug Therapy 2000. Philadelphia, PA: W.B. Saunders Company, 2000;7:1-22.
Page 60
Page 61
These items provide a global impression of the clinicians impression of the severity of each of these symptoms as
observed at the visit as well as during the week prior to the visit.
For items 15 17, a scale of 0 10 should be used:
0 = No symptoms
5 = Moderate symptoms
10 = Extreme symptoms
15. Core symptoms
These are the severity of the core symptoms for the three adult disorders for which algorithms have been developed:
mania, depression, positive psychotic symptoms, and negative symptoms.
16. Other symptoms
These include other symptoms that are commonly seen in individuals with mental disorders and include: irritability,
mood lability, agitation, anxiety, level of interest, appetite, energy, and insomnia. A space is left in case the clinician
wishes to add additional symptoms that may be present in a given patient.
17. Overall side effect severity
Rate the overall level of side effect severity from all medications being taken by the patient.
18. Suicidal or homicidal
Indicate if the patient is presently suicidal or homicidal and, if yes, please comment in the progress note section.
19. Overall functioning
Rate from 0 10 (0 = Low and 10 = High) your overall impression of the patients ability to function on a daily basis.
Please note: this is not a GAF score, but the clinician's overall impression of how the patient has been functioning
during the last week.
20. Are serum concentrations needed?
This provides a prompt for the clinician to order medication serum concentrations if they are needed. If yes, please
specify in the progress note section.
21. Rationale for diagnostic and other services
The rationale for ordering diagnostic and other services should be clearly documented.
22. Medication response
Please indicate the patients response to the medication since the beginning of the current stage. Check the box that
applies. Please note that this is medication response and, depending on comorbidity and the patients psychosocial
situation, this may not necessarily represent the patients overall improvement in mental health status.
23. Rationale for change in medication
If medication is being changed (including dose changes), please note rationale by checking all boxes that apply.
24. Prescription information
o This information should be completed regardless of whether a patient is getting a new prescription for
ongoing medications.
o List all medications being taken by the patient for the core syndrome, other symptoms, or side effects.
o Indicate via check mark, if this is a new medication, continuation of a previous medication, or medication
being discontinued at this visit.
o Provide the following information: dose, frequency, duration the medication is to be taken, titration (or
tapering) schedule, and any other pertinent information describing the medication or use of this
medication.
o Indicate via check mark the following:
S = Core symptoms
OS = Other symptoms
SE = Side effects of S or OS medications
25. Algorithm State at End of Visit
A change in core disorder medications during the visits dictates a change in the algorithm stage.
Page 62
Page 63